Literature DB >> 1357242

Randomised controlled trial of cost-effectiveness of lithotripsy and open cholecystectomy as treatments for gallbladder stones.

J P Nicholl1, J E Brazier, P C Milner, L Westlake, B Kohler, B T Williams, B Ross, E Frost, A G Johnson.   

Abstract

Inpatient extracorporeal shockwave lithotripsy for treatment of gallbladder stones has not previously been compared with open cholecystectomy in terms of cost-effectiveness. In a randomised controlled trial, 163 patients, stratified by gallstone bulk (over 4 cm3 or not), were randomised to lithotripsy or cholecystectomy (38 large-bulk and 27 small-bulk cholecystectomy; 37 large-bulk and 61 small-bulk lithotripsy) and followed up for 1 year. Both treatments gave significant health gains in terms of a reduction in episodes of biliary pain, improved perceived health status, and symptom relief, but few differences between treatments were found. There was some evidence that biliary-pain episodes were less severe after cholecystectomy. Cholecystectomy patients also had greater improvements in mean health gain for three related symptoms: vomiting, feeling sick, and fatty-food upset. However, there were no differences between groups in perceived health status. Among lithotripsy patients, health gain was not related to stone clearance. Lithotripsy was more expensive than cholecystectomy, principally because of the costs of the inpatient stay and adjuvant bile-salt therapy. Conventional lithotripsy appears at least as cost-effective as cholecystectomy for patients with small-bulk stones but less cost-effective for those with large-bulk stones. To some extent treatment choice can be guided by patient preference.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1357242     DOI: 10.1016/0140-6736(92)92682-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  8 in total

Review 1.  Persistent and de novo symptoms after cholecystectomy: a systematic review of cholecystectomy effectiveness.

Authors:  Mark P Lamberts; Marjolein Lugtenberg; Maroeska M Rovers; Anne J Roukema; Joost P H Drenth; Gert P Westert; Cornelis J H M van Laarhoven
Journal:  Surg Endosc       Date:  2012-10-06       Impact factor: 4.584

Review 2.  The Short-Form 36 (SF-36) Health Survey and its use in pharmacoeconomic evaluation.

Authors:  J Brazier
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

3.  Extracorporeal shock wave lithotripsy and gall bladder stones.

Authors:  A G Johnson; B Ross
Journal:  Gut       Date:  1993-09       Impact factor: 23.059

4.  Predictions and associations of cholecystectomy in patients with cholecystolithiasis treated with extracorporeal shock wave lithotripsy.

Authors:  H E Adamek; C Rochlitz; A C Von Bubnoff; D Schilling; J F Riemann
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.199

Review 5.  Evidence-based clinical practice guidelines for cholelithiasis 2016.

Authors:  Susumu Tazuma; Michiaki Unno; Yoshinori Igarashi; Kazuo Inui; Kazuhisa Uchiyama; Masahiro Kai; Toshio Tsuyuguchi; Hiroyuki Maguchi; Toshiyuki Mori; Koji Yamaguchi; Shomei Ryozawa; Yuji Nimura; Naotaka Fujita; Keiichi Kubota; Junichi Shoda; Masami Tabata; Tetsuya Mine; Kentaro Sugano; Mamoru Watanabe; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2016-12-10       Impact factor: 7.527

6.  Symptoms and health status before and six weeks after open cholecystectomy: a European cohort study.ECHSS Group. European Collaborative Health Services Study Group.

Authors:  N A Black; E Thompson; C F Sanderson
Journal:  Gut       Date:  1994-09       Impact factor: 23.059

7.  Cost effectiveness of adjuvant bile salt treatment in extracorporeal shock wave lithotripsy for the treatment of gall bladder stones.

Authors:  J P Nicholl; B Ross; P C Milner; J E Brazier; L Westlake; B Kohler; E Frost; B T Williams; A G Johnson
Journal:  Gut       Date:  1994-09       Impact factor: 23.059

8.  Abdominal symptoms: do they disappear after cholecystectomy?

Authors:  M Y Berger; T C Olde Hartman; A M Bohnen
Journal:  Surg Endosc       Date:  2003-06-17       Impact factor: 4.584

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.